Slu -pp-332 yog dab tsi?
SLU-PP-332 yog ib qho hluavtaws me me uas ua raws li Kev Ua Si Mimetic, ua raws li cov txiaj ntsig ntawm tes ntawm kev tawm dag zog los ntawm kev ua kom Estrogen-Related Receptors (ERRs). Tsim los ntawm cov kws tshawb fawb ntawm Washington University School of Medicine, qhov sib xyaw no ua rau muaj kev siv zog thiab cov roj oxidation, txo cov rog rog, txhim kho insulin rhiab heev, thiab txhim kho kev ua siab ntev, muaj peev xwm muab txoj hauv kev kho tshiab rau kev rog rog, metabolic syndrome, thiab nqaij atrophy.
Yog li, Slu-pp-332 ua li cas? Hauv cov ntsiab lus yooj yim, nws ua haujlwm ntawm qhov tseem ceeb tshaj plaws ntawm tib neeg kev ua haujlwm: lub cell.
Slu-pp-332 ncaj qha hais txog qhov kev poob qis no. Nws cov teebmeem tseem ceeb suav nrog:
Txhim kho lub cev kev ua tau zoo & rov qab: Cov neeg siv qhia txog kev ua kom muaj zog, muaj zog, thiab muaj peev xwm ua haujlwm. Qhov tseem ceeb tshaj, nws txo qis cov leeg mob thiab ua kom rov zoo los ntawm kev tawm dag zog tawm dag zog- ntxias oxidative kev nyuaj siab, ua rau koj rov qab mus rau koj qhov kev cob qhia sai dua thiab muaj zog dua.
Cellular Longevity Support: Kev tshawb fawb qhia tias kev txhawb nqa kev noj qab haus huv mitochondrial yog qhov tseem ceeb rau kev txhawb nqa kev laus noj qab haus huv. Slu-pp-332 pab tiv thaiv cov organelles tseem ceeb ntawm kev puas tsuaj, txhawb tsis yog li koj ua hnub no, tab sis koj qhov tseem ceeb rau xyoo tom ntej.
Hauv cov ntsiab lus yooj yim, nws yog qhov sib xyaw ua ke uas tuaj yeem "qhib" cellular zog metabolism-txog receptors (ERRs), uas yog kev tshawb fawb muaj txiaj ntsig rau kev txhim kho cov leeg nqaij thiab kho cov teeb meem metabolic.
SLU-PP-332 qhia kev txhim kho koob tshuaj:
1.Obesity thiab Insulin Resistance: Hauv kev noj zaub mov-mob rog rog, kev kho 4 lub lis piam (50 mg / kg / hnub) txo cov rog rog los ntawm 20%, yoo ntshav qabzib los ntawm 30%, thiab txhim kho insulin rhiab heev los ntawm 50%
2.Mitochondrial Biogenesis: Nce mitochondrial DNA cov ntsiab lus los ntawm 2.5-fold nyob rau hauv cov leeg pob txha, mirroring endurance kev cob qhia los
3.Kev laus thiab lub cev tsis ua haujlwm: Hauv cov nas muaj hnub nyoog, 25 mg / kg / hnub rov qab rau lub raum thiab lub siab ua pa mitochondrial, txo cov cim kev ntxhov siab oxidative (xws li malondialdehyde, 8-OHdG) los ntawm 40%.
Cov lus qhia yav tom ntej
1.Clinical Development:
- Phase I Trials: Txhawm rau ntsuas kev nyab xeeb, kam rau ua, thiab chaw muag tshuaj hauv cov neeg tuaj yeem noj qab haus huv.
- Biomarker Identification: Siv tau PGC-1 thiab CPT1B raws li tus neeg sawv cev kawg rau kev ua tau zoo.
2.Drug Design Innovations:
- Structure-Kev Sib Raug Zoo (SAR) Kev Kawm: Ua kom zoo ERR xaiv siv cryo-EM thiab molecular dynamics.
- Prodrug Formulations: Txhim kho qhov ncauj bioavailability ntawm ester prodrugs (piv txwv li, SLU-PP-332-acetate).
3.Kev kho mob sib xyaw ua ke: Co- kev tswj hwm nrog GLP-1 agonists (piv txwv li, semaglutide) lossis SGLT2 inhibitors (xws li, empagliflozin) tuaj yeem muab cov txiaj ntsig ntxiv rau kev tswj glycemic thiab poob phaus.
4.Targeted Delivery Systems: Nanoparticle-encapsulated SLU-PP-332 tuaj yeem txo qis - lub hom phiaj cuam tshuam. Cov kev tshawb fawb ua ntej qhia PEG-PLGA nanoparticles txhim kho cov leeg pob txha los ntawm 70%.
